Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Revenue (2023 - 2025)

Kura Oncology (KURA) has disclosed Revenue for 3 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 4401.74% to $17.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.7 million, a 2428.84% increase, with the full-year FY2025 number at $67.5 million, up 25.24% from a year prior.
  • Revenue was $17.3 million for Q4 2025 at Kura Oncology, down from $20.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $20.8 million in Q3 2025 to a low of -$412000.0 in Q3 2024.
  • A 3-year average of $3.1 million and a median of -$394000.0 in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: dropped 9.34% in 2024, then surged 5136.41% in 2025.
  • Kura Oncology's Revenue stood at -$394000.0 in 2023, then dropped by 2.28% to -$403000.0 in 2024, then skyrocketed by 4401.74% to $17.3 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Revenue are $17.3 million (Q4 2025), $20.8 million (Q3 2025), and -$382000.0 (Q1 2025).